To obtain images by Positron Emission Tomography (PET) of the 18F-PSMA in patients with suspected or recurrent metastatic prostate cancer or recurrent prostate cancer.
Descripción
The PET/CT -18F-PSMA provides semi-quantitative metabolic imaging of abnormal prostate-specific membrane antigen (PSMA) concentrations enabling accurate assessment of prostate cancer, identifying threshold prostate-specific antigen (PSA) levels for optimal detection of recurrent prostate cancer (RC).
The level of PSMA expression has prognostic value for disease progression, both primary and metastatic.
Category: BIOMARKER
Sub - Category: Diagnostic product for “in vivo” use”
| Unit | DOSAGE |
|---|---|
| Presentation | Presentation: solution for intravenous (i.v.) injection, radioactive, sterile and free of bacterial endotoxins, contained in a borosilicate glass vial closed with a butyl rubber stopper. |
| Size / Activity | N/A |
| Availability | N/A |
![3’-deoxi-[<sup>18</sup>F]-fluorotimidina (<sup>18</sup>F-FLT) solución.](https://tecnonuclear.com/wp-content/uploads/2025/12/ffly-300x300.jpg)
